FAKTOR OPTIONSSCHEIN - IDORSIA | Delayed Deutsche Boerse AG 10:21:22 2024-05-17 EDT | ||
| 0.15 EUR | -15.73% |
|
| Current month | +58.93% | ||
| 1 month | +11.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.15 | -15.73% |
| 24-05-16 | 0.178 | +2.30% |
| 24-05-15 | 0.174 | +5.45% |
| 24-05-14 | 0.165 | -5.17% |
| 24-05-13 | 0.174 | +16.78% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 10:21 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | 
BNP Paribas
|
| WKN | PN21D0 |
| ISIN | DE000PN21D08 |
| Date issued | 2021-12-08 |
| Strike | 2.352 CHF |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 77.96 € |
|---|---|
| Lowest since issue | 0.102 € |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.352
CHF
Average target price
1.724
CHF
Spread / Average Target
-26.71%
- Stock Market
- Certificates
- Certificat